Recent Updates
Recently added Catalysts
MEDP Neutral Sentiment

Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026

Key Takeaway: Medpace Holdings, Inc. has announced that it will report its financial results for the second quarter of 2026 on July 22, 2026. This announcement provides stakeholders with a timeline for when to expect the financial performance details of the company. The report will likely include insights into the company's operations and financial health.
Price reaction · baseline $461.6 (2026-06-16 close) · hit after-hours · clean, no other MEDP news in the window
day 0 close · peak
-1%

Market Sentiment Analysis

Full Press Release Details

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2026 financial results after the market close on Wednesday, July 22, 2026. The Company will host a conference call the following morning, Thursday, July 23, 2026, at 9:00 a.m. ET to discuss these results.
To participate in the conference call, interested parties must register in advance by clicking onthis link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.
To access the conference call via webcast, visit the “Investors” section of Medpace’s website atinvestor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,300 people across 46 countries as of March 31, 2026.
Last updated: Jun 16, 2026